匿堂壤连!Q塑生!魍筮!!鲞箜!嬲丛鲤垫坐曼!!嬲i垒丛坐:』坚呈Q嫂:!堂:!!:盟!:!
【7】
(8]
【9】
【10]
【11】
[12]
[13]
【14j
[15]
(16]
[17]
【lg】
囔静.辇凌众演蛋囊酶及葵捧麓秘与舞鬃臻转移瓣疆究遴疆
[jj.阖终医学如产科学分册,2005,32(1):54-56.
Herrera CA,Xu L,Bueana CD。et a1.Expression of
metastasis.re-
lated
genes
in
human epithelial
ovarian
tumors[J].ht
J Oncol,
2002,20(1):5—13.
Mitsiades N,Y#WH,Poulaki V。雒a1.Matrix metallopmteinase-7.
Mediated cleavage of
faslig
and
protect stumor
ceils from ehemo the
rapeutied
rugey
to
oxicity【J1.Cancer Res,2001,61(2):577-581.
Nishikawa A,1wasaki M,Akutagawa
N,et
a1.Expression of
various
matrix
proteases
and Ets family transcriptional factors
in
ovarian
cancer
celllines:correlation
to
invasive
potential【J】.Gynecol
On-
col,2000,79(2>:256_263.
Huang
S,VanArsdallM,Tedjarnti
S,eta/,Contributionsof stromal
metallopreteinase-9
to
angiogenesis
and growth of human
ovarian
carcinoma in
mice[J].J
Natl
Cancer
Inst,2002,94(15):
1134.1 142.
Lemy・Dudal J,Demeilliem C。G胡let O,et
a1.Transmigration
of hu—
mall
ovarian adenocareinoma
cells throllgh endothelialextraeellular
matrix
involves_v
integrins
and the
participation
of
MMP2[J】。轴
J
Cancer,2005
114(12):53l-543.
Murthi P,Barker G,Nowell CJ,et a1.PIasm inogen fragmentation
and increased production of extraeellularmatrix.degrading
protein.
age ale
associated
with
serous
epithelial
ovarian
progression[J】.
Gynecol Oncol,2004,92(1):80¥8。
Shigemasa K,Tanimoto H,Sakata K。越a1.Induction ofmatrix
met-
alloFotease-7
is common in mncinous
ovarian
tumors
including early
stage
diserse[J].Med
Oncol,2000。17(1):52-61.
Sakata K,Shigemasa K,Nagai N,et a1.Expression ofmatrix metal.
10proteinases(MMP2。MMp9.MTl一^藿MP)and
their inhibitors
《TIMPl,TIMP2)in
common epithelialtumors
oftheovary[j】.hat
j
Oncol,2000,17(4):673-681.
Murphy PM.Chemokines and the molecular basis 0f
cancer
metas-
tasis[J].N
Engl J
Med,2001,345(11):833-835.
蔡威,宋今丹.撼质金属蛋白酶及其组织抑制物在卵巢肿瘤巾
鹣表达f J],筑疰,2002,21(1):91-94.
Kim TJ。嚣聂o SB。Choi YL.篚a1.High
expression
oftissue inhibitor
of metalloproteinase-2
in
serous
ovarian
carcinomas
and
the role of
this
expression
in
ovarian tumorigenesis[J].Hum
Pathol,2006,37
(7):906.913.
【19】
[203
[21】
[22】
[23]
【24】
[25]
【26]
[27】
[28]
【嚣】
-65・
Fumya M,1.,shikura H,Kawarada Y,et
a/。Expression
of
matrix
metallopFoteinases
and。related
tissue
inhibitors
in
the
cyst
fluids of
ovariart mucinous
neoplasnls[J].Gynecol Oncol,2000,78(2):
106.1 12.
Demeter A,Szlrmai K。OIah
J,甜a/Elevated
expression of
matrix
metalloptroteinase-9and
flbronectin
concentration in
recurrent
epi.
thelial
Ovarian
cancer[J】。Orv
Hetil,2004,145(31):1617・1624,
Thorgeirsson
UP,Yoshiji
H,Sinha CC,et a1.Breast
cancer,tumor
noavascalature and the effect
of tissue
inhibitor
of
metalloproteinas.
e¥-l(TMP-1)on
Angiogenesis[J].In
Vivo,1996,10(2):
137.140.
Kim l,Kim HG。Moon SO。et
a1.Angiopoietin.1
induces endothelial
cellSpmuting through the activationof focal
adhe.sion
kinase and
plasmin
secretion(J].Circ Res,2000,86(9):952母59.
Patterson BC,Sang
QXA.Angiostatin—converting
enzyme
activities
of Human Matrily
sin(MMP-7)and
gelatinase
B/type
1V
collage-
nase(MMP-9)[J】.J
Biol
Chem,1997,272(46):28823-28825.
Hantke
B,Harbeck
N,Sehmalfeldt
B,et
a1.Clinical relevance of
matrix
metatloproteinase.13 determined with
a
new
highly
specific
and
sensitive
ELISA in
ascitic
fluid of
advanced
ovarian
carcinoma
patients【JJ.Biol Chem,2003,384(8):1247—1251.
胡晓霞,李力,黎捋戎,等.基质金属蛋白酶MMP母及其组织抑
铡测TlMP—l在郛黎瓣癯中的表达及意义[J】,孛潮妇产辩牾
凑杂盍,2004,5(2);123.1赞,
Wu
X,Li
H,Kang
L,et a1.Activated
matrix
metalloproteinase-2.
apotential marker of
prognosis
for epithelial
ovarian
cancer[J].Gy-
necol Oncol,2002.84(8):126一134.
Tomg
PL。Man
TL.Chan WY.雕a1.Prognostic significance of stre-
mal metalloproteinase-2
in ov矗rian
adenocarcinoma and
its
relation
to
carcinoma
progression【j j.Gynecol
Oncol,2004,92(4》:
559-567.
Kamat AA,FIetcher M.Gruman LM,et a1.The clinical rele2va
nce
of
st
romal
mat
rixmetallop roteinase
exp
i_ession
in
ovarla
nca ncer
【J1.Clin
Cancer
Res,2006,12(6):1707.1714.
Lakka
SS,Raian
M,Condi
C+et
a1.Adenovirus-mediated
a曜黔
sion of
antisense
MMP-9
in
glioma
cells inhibits
tumor
growth and
invasion【Jj.Oncogene,2002。21(5):801
1-8019.
收稿日期:2008-07-09修回日期:2008.10-15
维生素D及其受体在妇科肿瘤中的研究进展
林
兰A(综述),郑
秀(审校)
<禳建叛辩大学瓣鬟繁一医菝羟产辩,鼷髑350005)
中圈分类号:R737.3
文献标识鹤:A
文黛编号:1006-2084(2009)01-0065-04
擒要:维生囊D受体(VDR)楚奔导l,25二疑维生素B3发撂嶷转效应的核农生物大分子,菇类
瓣薛激素/甲获撩受落起家族残燕。l,25二羟缍燕素D3是橥垒褰转鳇活整形武,它除了英凑钙、磷
代谢调节作用井,还能调节正常组织和肿瘤细胞的生长和分化。VDR基因上存农多个多态性戗点,
鸯部分肿瘤的发生发展密切相关。本文主要综述VDR的结构及熊功能、基因多态性,维生素D的细
胞作用机制及与妇科肿瘤的相关性研究。
荚键谲:维童豢D;维生素D受露;据翳脖瘰
Research Advances of Vitamin D
and
Its Receptor in Gynecologic Tumor 班N/an.ZHENG Xiu.(De-
partment
of
Obstetrics&Gynecology,the
First
A.融ed
Hospital
of Fufian
Medical University.Fudwu
350005.China)
Abstract:弧e
vitumin
D
receptor(VDR)is
intranuclear
Biological㈣remoleeules.The
biologieal
ae.
tions of l,25・Dihydroxyvitamin D3 a辩primarily mediated by the VDR,which belongs
to the
superfamily of
steriod/thyroid hormone nuclear
receptors.强e
vitamin
D,l,25.Dihydroxyvitamin
D,is
the
active
metabolite
of vitamin
D,aoart
from
tlle
metabolic regulation of calcium
and
phosphate。it has
normal
regulation
and
tUmor
eell growth and differentiation+The
VDR gene
exists several polymorphisms。which is closely related
to
part
of
the tumor
ocettrrence
and
development.This
article
reviewed
the
structure,function
and
genetic
poly.
morphisms of VDR
gene,and
the cellular mechanism
of vitamin D in
gynecologic
oncdogy。
Key words:Vitamin
D;Vitamin
D receptor:Gynecologic tumor
透年来,亿疗在治疗多
数妇科恶性肿瘤孛发挥越来
越重要的作用,但是,化疗药
物存在较严重的毒性和耐药
性,限制了其在临床上的应
用。维生素D是人体必需
的维生索,除了调节体内钙、
磷代谢之外,还具有诱导细
臆分化、搀剜细胞增殖、促进
肿瘤细胞凋亡以及免疫调节
作用。在卵巢癌、子宫内膜
癌及宫颈癌中已检测到维生
素p受体(vitamin
D recep-
万方数据